Hospital Acquired Infections Therapeutic Market, By Drug Type (Antibacterial drugs, Antifungal drugs, and Antiviral drugs), By Route of Administration, By Infection Type, By Country, and By Region: Industry Analysis, Market Size, Market Share, and Forecast from 2025 to 2032
|
Report ID
AV3660
|
Published Date
April 2025
|
Pages
396
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Hospital Acquired Infections Therapeutic Market size was evaluated at USD 13,875 million in 2024, rising at a CAGR of 3.70% between 2025 and 2032.
Hospital-acquired infections (HAIs) are infections that patients acquire during their hospital stay, which were not present at the time of admission. Hospital-acquired infection control involves a range of measures aimed at preventing and managing these infections through effective cleaning, sterilization, and disinfection practices. These infections can result from the cross-contamination of equipment surfaces, patient skin, and healthcare staff. Infection control protocols in hospitals are designed to minimize or eliminate the transmission of diseases, ensuring a safer environment for both patients and healthcare workers.
Hospital Acquired Infections Therapeutic Market- Market Dynamics
Ø Increasing healthcare expenditures fuel market Growth
The growing cost of healthcare is expected to drive the expansion of the hospital-acquired infection control market. Healthcare expenditures encompass the total spending on healthcare services, products, and activities over a specific period, whether at the individual, community, national, or global level. As healthcare spending increases, hospitals and healthcare facilities are allocating more resources to adopt advanced infection prevention technologies. These include cutting-edge solutions such as sophisticated disinfection systems, smart monitoring devices, and other innovations designed to enhance infection control measures. For example, in May 2024, the Office for National Statistics, a UK-based government agency, reported a 5.6% increase in total healthcare expenditure in nominal trms between 2022 and 2023, up from 0.9% in 2022. This upward trend in healthcare spending is expected to fuel future growth in the hospital-acquired infection control market.
Hospital Acquired Infections Therapeutic Market- Segmentation Analysis:
The global release liner market is divided into four groups: Drug Type, Route of Administration, Infection Type, and geography.
The hospital-acquired infections (HAI) therapeutics market is categorized into four drug types: antibacterial drugs, antifungal drugs, antiviral drugs, and others. In 2023, antibacterial drugs generated the highest revenue, amounting to approximately USD 9.2 billion. This dominance is attributed to bacteria being the primary causative agents of HAIs, necessitating widespread use of antibacterial treatments. The increasing prevalence of antibiotic-resistant bacteria in healthcare settings has further heightened the demand for effective antibacterial medications.
Regarding infection types, the market is divided into surgical site infections, urinary tract infections, bloodstream infections, ventilator-associated pneumonia, and other hospital infections. In 2023, bloodstream infections (BSIs) accounted for the largest market share, generating approximately USD 5.6 billion. BSIs, also known as sepsis or bacteremia, are severe infections resulting from pathogens entering the bloodstream. They can lead to complications such as septic shock, organ failure, and death. BSIs are a major cause of morbidity and mortality, particularly among critically ill patients. The increasing number of immunocompromised patients and the use of invasive medical devices contribute to the rising incidence of BSIs, highlighting the need for effective therapeutic strategies.
Hospital Acquired Infections Therapeutic Market- Geographical Insights
The Hospital-Acquired Infections (HAIs) Therapeutics Market is geographically diverse, spanning Europe, the Middle East, North America, Asia Pacific, Africa, and Latin America. These regions are further segmented by the nations driving commercial activities. In 2024, Europe led the market, a trend expected to persist throughout the forecast period. This dominance is attributed to the high prevalence of HAIs in European countries, coupled with increasing approvals and launches of innovative HAI therapeutics. The strong presence of major pharmaceutical companies like GlaxoSmithKline Plc, F. Hoffmann-La Roche AG, Allergan Plc, and Bayer AG has further boosted the availability of novel HAI treatments, supporting regional market growth.
In contrast, the Asia Pacific region is anticipated to witness substantial growth in the HAI therapeutics market during the forecast period. This surge is driven by the rising prevalence of chronic diseases in emerging economies such as India and China, leading to more hospitalizations. For instance, according to Globocan, around 4,285,033 new cancer cases were diagnosed in China in 2018. The increasing rate of HAIs, coupled with higher hospitalization rates, is expected to fuel demand for HAI therapeutic drugs and propel regional growth.
Hospital Acquired Infections Therapeutic Market- Competitive Landscape:
The HAI therapeutics market is highly competitive, with major pharmaceutical companies such as Merck & Co., Abbott, F. Hoffmann-La Roche, AbbVie, and Allergan Plc leading the charge in developing innovative antibiotics and antimicrobial therapies. Additionally, emerging biotech firms are exploring niche treatments, including monoclonal antibodies and bacteriophage therapy. Collaborations between established pharmaceutical giants and startups are becoming increasingly common, aimed at enhancing drug development and addressing the growing burden of HAIs. As antibiotic resistance continues to rise, competition within the market intensifies, underscoring the urgent need for effective treatments and improved patient outcomes. A notable example is Basilea Pharmaceutica International Ltd., which achieved a significant milestone in April 2024 when the FDA approved its new bloodstream infection treatment, Zevtera. This approval strengthens Basilea\'s position as a leader in HAI therapies, expanding treatment options for severe infections and enhancing patient outcomes.
Recent Developments:
v October 2023: Spartan Medical Inc. launched a nationwide campaign in the United States to raise awareness about surgical site infections (SSIs) and their consequences. This initiative aims to educate healthcare professionals and patients about SSI risks and the importance of prevention, driving demand for advanced infection control measures and therapeutic solutions. The campaign reinforces Spartan Medical’s commitment to addressing critical healthcare challenges.
v April 2022: Pfizer announced a definitive agreement to acquire ReViral, a clinical-stage biopharmaceutical company specializing in antiviral therapies for respiratory syncytial virus (RSV). This acquisition enhances Pfizer’s presence in the antiviral therapeutics sector and supports its efforts to develop new treatments for RSV and other respiratory infections.
v December 2021: Merck (known as MSD outside the U.S. and Canada) and Ridgeback Biotherapeutics announced that their antiviral drug, molnupiravir, received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for treating COVID-19. This development marks a significant advancement in the global fight against COVID-19, reinforcing Merck’s reputation for innovative drug development that improves patient outcomes and addresses major health threats.
SCOPE OF THE REPORT
This report\'s scope includes the following important market segments:
GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Ø Merck & Co.
Ø Abbott
Ø F. Hoffmann-La Roche
Ø AbbVie
Ø Allergan Plc
Ø Eugia Pharma
Ø Bayer
Ø DAIICHI SANKYO COMPANY
Ø Glenmark Pharmaceuticals
Ø GSK
Ø Hikma Pharmaceuticals
Ø Melinta Therapeutics
Ø Pfizer
Ø Sanofi
Ø Viatris
Ø Others
GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032
Ø Antibacterial drugs
Ø Antifungal drugs
Ø Antiviral drugs
Ø Other drug types
GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
Ø Intravenous (IV)
Ø Topical
Ø Oral
Ø Inhalation
GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY INFECTION TYPE- MARKET ANALYSIS, 2019 - 2032
Ø Surgical site infections
Ø Urinary tract infections
Ø Bloodstream infections
Ø Ventilator-associated pneumonia
Ø Other hospital infections
GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
Ø North America
o The U.S.
o Canada
Ø Europe
o Germany
o France
o Italy
o Spain
o United Kingdom
o Russia
o Netherlands
o Sweden
o Poland
o Rest of Europe
Ø Asia Pacific
o India
o China
o South Korea
o Japan
o Australia
o Thailand
o Indonesia
o Philippines
o Rest of APAC
Ø Latin America
o Brazil
o Mexico
o Argentina
o Colombia
o Rest of LATAM
Ø The Middle East and Africa
o Saudi Arabia
o United Arab Emirates
o Israel
o Turkey
o Algeria
o Egypt
o Rest of MEA
TABLE OF CONTENT
1. Hospital Acquired Infections Therapeutic Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Hospital Acquired Infections Therapeutic Market Snippet by Drug Type
2.1.2. Hospital Acquired Infections Therapeutic Market Snippet by Route of Administration
2.1.3. Hospital Acquired Infections Therapeutic Market Snippet by Infection Type
2.1.4. Hospital Acquired Infections Therapeutic Market Snippet by Country
2.1.5. Hospital Acquired Infections Therapeutic Market Snippet by Region
2.2. Competitive Insights
3. Hospital Acquired Infections Therapeutic Key Market Trends
3.1. Hospital Acquired Infections Therapeutic Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Hospital Acquired Infections Therapeutic Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Hospital Acquired Infections Therapeutic Market Opportunities
3.4. Hospital Acquired Infections Therapeutic Market Future Trends
4. Hospital Acquired Infections Therapeutic Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Hospital Acquired Infections Therapeutic Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Hospital Acquired Infections Therapeutic Market Landscape
6.1. Hospital Acquired Infections Therapeutic Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Hospital Acquired Infections Therapeutic Market – By Drug Type
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
7.1.2. Antibacterial drugs
7.1.3. Antifungal drugs
7.1.4. Antiviral drugs
7.1.5. Other drug types
8. Hospital Acquired Infections Therapeutic Market – By Route of Administration
8.1. Overview
8.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
8.1.2. Intravenous (IV)
8.1.3. Topical
8.1.4. Oral
8.1.5. Inhalation
9. Hospital Acquired Infections Therapeutic Market – By Infection Type
9.1. Overview
9.1.1. Segment Share Analysis, By Infection Type, 2024 & 2032 (%)
9.1.2. Surgical site infections
9.1.3. Urinary tract infections
9.1.4. Bloodstream infections
9.1.5. Ventilator-associated pneumonia
9.1.6. Other hospital infections
10. Hospital Acquired Infections Therapeutic Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
10.2.1. Overview
10.2.2. Hospital Acquired Infections Therapeutic Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.2.6. North America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.3.8. Italy
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.8.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.8.5. Italy Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.3.9. United Kingdom
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.9.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.9.5. United Kingdom Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.3.10. France
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.10.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.10.5. France Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.3.11. Russia
10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.11.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.11.4. Russia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.3.12. Netherlands
10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.12.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.12.4. Netherlands Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.3.13. Sweden
10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.13.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.3.14. Poland
10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.14.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.14.4. Poland Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.3.15. Rest of Europe
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.15.5. Rest of the Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Asia Pacific
10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.6. Asia Pacific Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.4.7. India
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.7.5. India Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.4.8. China
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.8.5. China Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.4.12. Thailand
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.12.5. Thailand Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.4.13. Indonesia
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.13.5. Indonesia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.5. Latin America
10.5.1. Overview
10.5.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Latin America
10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.5.6. Latin America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
10.6.1. Overview
10.6.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Middle East and Africa
10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.6. Middle East and Africa Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.6.8. United Arab Emirates
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.8.5. United Arab Emirates Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
11. Key Vendor Analysis- Hospital Acquired Infections Therapeutic Industry
11.1. Competitive Dashboard
11.2. Company Profiles
11.2.1. Merck & Co.
11.2.2. Abbott
11.2.3. F. Hoffmann-La Roche
11.2.4. AbbVie
11.2.5. Allergan Plc
11.2.6. Eugia Pharma
11.2.7. Bayer
11.2.8. DAIICHI SANKYO COMPANY
11.2.9. Glenmark Pharmaceuticals
11.2.10. GSK
11.2.11. Hikma Pharmaceuticals
11.2.12. Melinta Therapeutics
11.2.13. Pfizer
11.2.14. Sanofi
11.2.15. Viatris
11.2.16. Others
12. 360 Degree Analyst View
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
